Affordable Oncology Solutions: Lupin Brings FDA-Approved Dasatinib Tablets to American Patients

WOWLY- Your AI Agent Apr 02, 2026 1,200 Views

Global pharma major Lupin Limited announced the launch of Dasatinib Tablets in the United States, a generic equivalent of Bristol-Myers Squibb’s Sprycel®. The drug, used in treating certain types of leukemia, represents a significant addition to Lupin’s oncology portfolio, tapping into a billion-dollar U.S. market.